The PI3K Specific Inhibitor BKM120 Results Effective and Synergizes With Ruxolitinib In Preclinical Models Of Myeloproliferative Neoplasms

被引：7
|
作者：
Bartalucci, Niccolo
Bogani, Costanza
Martinelli, Serena
Mannarelli, Garmela
Villeval, Jean-Luc
Vannucchi, Alessandro M.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1599.1599
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1599
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO)
    Alipour, Faranak
    Riyahi, Niknam
    Safaroghli-Azar, Ava
    Sari, Soyar
    Zandi, Zahra
    Bashash, Davood
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2019, 116
  • [42] A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors
    Baselga, J.
    De Jonge, M. J.
    Rodon, J.
    Burris, H. A., III
    Birle, D. C.
    De Buck, S. S.
    Demanse, D.
    Ru, Q. C.
    Goldbrunner, M.
    Bendell, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] A phase Ib safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib (gef) in EGFR TKI-resistant NSCLC
    Tan, Daniel Shao-Weng
    Lim, Kiat Hon
    Tai, Wai Meng
    Ahmad, Aziah
    Pan, Summer
    Ng, Quan Sing
    Ang, Mei-Kim
    Gogna, Apoorva
    Ng, Yuen Li
    Tan, Bien Soo
    Lee, Haur Yueh
    Krisna, Sakktee Sai
    Lau, Dawn P. X.
    Zhong, Liz
    Iyer, Gopal
    Chowbay, Balram
    Lim, Alvin S. T.
    Takano, Angela
    Lim, Wan-Teck
    Tan, Eng-Huat
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] An exploratory analysis of inactivation of PI3K/AKT/mTOR signaling pathway using neoadjuvant BKM120 in PI3KCA mutated early breast cancer
    Estevez, L. G.
    Suarez, A.
    Calvo, I.
    Fernandez-Abad, M.
    Perea, S.
    Hidalgo, M.
    CANCER RESEARCH, 2013, 73
  • [45] Analysis of inactivation of PI3K/AKT/mTOR signaling pathway using neoadjuvant BKM120 in PI3KCA mutated early breast cancer.
    Laura, Estevez G.
    Ana, Suarez
    Isabel, Calvo
    Fernandez Abad, Maria
    Perea, Sofia
    Hidalgo, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] PI3K inhibition in preclinical models of HNSCC
    Hedberg, Matthew Louis
    Li, Hua
    Zeng, Yan
    Grandis, Jennifer Rubin
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [47] Synergism analysis of dose matrices for combinations of BKM120 (a PI3K inhibitor), MEK162 (a MEK1/2 inhibitor) and chemotherapy in colorectal cancer (CRC) cell lines
    Tosi, Diego
    Atis, Salima
    Mollevi, Caroline
    Martineau, Pierre
    Gongora, Celine
    CANCER RESEARCH, 2014, 74 (19)
  • [48] Synergism analysis of dose matrices for combinations of BKM120 (a PI3K inhibitor), MEK162 (a MEK1/2 inhibitor) and chemotherapy in colorectal cancer (CRC) cell lines
    Tosi, Diego
    Atis, Salima
    Mollevi, Caroline
    Vie, Nadia
    Martineau, Pierre
    Gongora, Celine
    CLINICAL CANCER RESEARCH, 2015, 21
  • [49] PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA: AN IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM STUDY
    Wen, Patrick
    Yung, Alfred
    Mellinghoff, Ingo
    Lamborn, Kathleen
    Ramkissoon, Shakti
    Cloughesy, Timothy
    Rinne, Mikael
    Omuro, Antonio
    DeAngelis, Lisa
    Gilbert, Mark
    Chi, Andrew
    Batchelor, Tracy
    Colman, Howard
    Chang, Susan
    Nayak, Lakshmi
    Massacesi, Cristian
    DiTomaso, Emmanuelle
    Prados, Michael
    Reardon, David
    Ligon, Keith
    NEURO-ONCOLOGY, 2013, 15 : 134 - 134
  • [50] Phase I dose- escalation study of buparlisib ( BKM120), an oral pan- class I PI3K inhibitor, in Japanese patients with advanced solid tumors
    Ando, Yuichi
    Inada-Inoue, Megumi
    Mitsuma, Ayako
    Yoshino, Takayuki
    Ohtsu, Atsushi
    Suenaga, Naoko
    Sato, Masahiko
    Kakizume, Tomoyuki
    Robson, Matthew
    Quadt, Cornelia
    Doi, Toshihiko
    CANCER SCIENCE, 2014, 105 (03) : 347 - 353
12345